

Adrian M Di Bisceglie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5303651/publications.pdf>

Version: 2024-02-01

69
papers

4,403
citations

147726

31
h-index

110317

64
g-index

73
all docs

73
docs citations

73
times ranked

4953
citing authors

#	ARTICLE	IF	CITATIONS
1	Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon. <i>New England Journal of Medicine</i> , 2008, 359, 2429-2441.	13.9	445
2	Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. <i>Journal of Hepatology</i> , 2005, 43, 434-441.	1.8	310
3	Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in north america. <i>Hepatology</i> , 1998, 27, 1661-1669.	3.6	252
4	Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. <i>Gastroenterology</i> , 2016, 151, 1131-1140.e5.	0.6	199
5	Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: Just the tip of the iceberg?. <i>Hepatology</i> , 2015, 61, 703-711.	3.6	192
6	Optimal therapy of hepatitis C. <i>Hepatology</i> , 2002, 36, S121-S127.	3.6	186
7	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
8	Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. <i>American Journal of Gastroenterology</i> , 2003, 98, 2060-2063.	0.2	165
9	Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. <i>Hepatology</i> , 2000, 32, 135-138.	3.6	162
10	Optimal therapy of hepatitis C. <i>Hepatology</i> , 2002, 36, s121-s127.	3.6	134
11	Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells. <i>Journal of Virology</i> , 2017, 91, .	1.5	133
12	Issues in screening and surveillance for hepatocellular carcinoma. <i>Gastroenterology</i> , 2004, 127, S104-S107.	0.6	103
13	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 183-192.	2.4	90
14	Epidemiology and Clinical Presentation of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2002, 13, S169-S171.	0.2	86
15	DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. <i>Journal of Hepatology</i> , 2020, 73, 540-548.	1.8	85
16	Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. <i>Hepatology</i> , 1999, 29, 1884-1892.	3.6	84
17	Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma. <i>American Journal of Pathology</i> , 2016, 186, 242-247.	1.9	80
18	Hepatitis C Virus-Mediated Enhancement of MicroRNA miR-373 Impairs the JAK/STAT Signaling Pathway. <i>Journal of Virology</i> , 2015, 89, 3356-3365.	1.5	78

#	ARTICLE	IF	CITATIONS
19	Hepatitis C Virus Proteins Inhibit C3 Complement Production. <i>Journal of Virology</i> , 2012, 86, 2221-2228.	1.5	74
20	Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. <i>Virology</i> , 2006, 349, 347-358.	1.1	72
21	Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. <i>Gut</i> , 2017, 66, 1844-1852.	6.1	69
22	Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. <i>Hepatology</i> , 2011, 53, 1100-1108.	3.6	55
23	Transcriptional Repression of C4 Complement by Hepatitis C Virus Proteins. <i>Journal of Virology</i> , 2011, 85, 4157-4166.	1.5	51
24	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 776-783.	2.9	45
25	A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. <i>Nature Communications</i> , 2021, 12, 5503.	5.8	41
26	Hepatitis C Virus Suppresses C9 Complement Synthesis and Impairs Membrane Attack Complex Function. <i>Journal of Virology</i> , 2013, 87, 5858-5867.	1.5	40
27	Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2173-2178.	1.1	39
28	Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes. <i>Journal of Virology</i> , 2015, 89, 11549-11556.	1.5	37
29	Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. <i>Journal of Hepatology</i> , 2019, 71, 486-497.	1.8	37
30	Seroprevalence of Viral Hepatitis in an Older Nursing Home Population. <i>Journal of the American Geriatrics Society</i> , 1999, 47, 1110-1113.	1.3	35
31	Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. <i>Liver Transplantation</i> , 2000, 6, 715-720.	1.3	32
32	Spontaneous retroperitoneal and rectus muscle hemorrhage as a potentially lethal complication of cirrhosis. <i>Liver International</i> , 2006, 26, 1291-1293.	1.9	30
33	Hepatitis C Virus Infection Upregulates CD55 Expression on the Hepatocyte Surface and Promotes Association with Virus Particles. <i>Journal of Virology</i> , 2013, 87, 7902-7910.	1.5	28
34	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2541-2551.e2.	2.4	28
35	HIV-HBV coinfection among South African patients receiving antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 499-503.	0.6	24
36	A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. <i>PLoS ONE</i> , 2018, 13, e0196908.	1.1	23

#	ARTICLE	IF	CITATIONS
37	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140.	3.6	23
38	Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: The null responder. <i>Journal of Medical Virology</i> , 2006, 78, 446-451.	2.5	22
39	Chemoprevention of hepatocellular carcinoma: Use of tamoxifen in an animal model of hepatocarcinogenesis. <i>Translational Research</i> , 2005, 145, 134-138.	2.4	19
40	Pretransplant treatments for hepatocellular carcinoma: Do they improve outcomes?. <i>Liver Transplantation</i> , 2005, 11, S10-S13.	1.3	19
41	Epstein-Barr Virus-Associated Acute Liver Failure Present in a 67-Year-Old Immunocompetent Female. <i>Gastroenterology Research</i> , 2016, 9, 74-78.	0.4	18
42	Template-dependent multiple displacement amplification for profiling human circulating RNA. <i>BioTechniques</i> , 2017, 63, 21-27.	0.8	18
43	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 856-865.	1.0	17
44	Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. <i>Journal of General Internal Medicine</i> , 2020, 35, 1011-1020.	1.3	16
45	High-Resolution Quantification of Hepatitis C Virus Genome-Wide Mutation Load and Its Correlation with the Outcome of Peginterferon-Alpha2a and Ribavirin Combination Therapy. <i>PLoS ONE</i> , 2014, 9, e100131.	1.1	15
46	Inhibition of C3 Convertase Activity by Hepatitis C Virus as an Additional Lesion in the Regulation of Complement Components. <i>PLoS ONE</i> , 2014, 9, e101422.	1.1	15
47	Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus. <i>Journal of Immunology</i> , 2016, 197, 1127-1136.	0.4	14
48	Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. <i>Contemporary Clinical Trials</i> , 2017, 57, 58-68.	0.8	13
49	Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia. <i>Lipids in Health and Disease</i> , 2020, 19, 239.	1.2	12
50	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021, 73, 1637-1651.	3.6	11
51	Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. <i>Liver International</i> , 2021, 41, 692-704.	1.9	11
52	A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. <i>Hepatology</i> , 2021, 74, 2952-2964.	3.6	7
53	Genetic characterization of hypervariable region 1 in patients chronically infected with hepatitis C virus genotype 2. <i>Journal of Medical Virology</i> , 2001, 64, 325-333.	2.5	6
54	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1526-1538.	1.0	6

#	ARTICLE	IF	CITATIONS
55	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. <i>Hepatology Communications</i> , 2021, 5, 538-547.	2.0	6
56	Diagnostic and therapeutic approach to hepatocellular carcinoma in the USA. <i>Hepatology Research</i> , 2007, 37, S251-S253.	1.8	3
57	In-depth serum virome analysis in patients with acute liver failure with indeterminate etiology. <i>Archives of Virology</i> , 2020, 165, 127-135.	0.9	3
58	Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy. <i>Journal of General Virology</i> , 2016, 97, 334-343.	1.3	3
59	HCV Genome-Wide Genetic Analyses in Context of Disease Progression and Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e103748.	1.1	3
60	Within-host quantitation of anellovirus genome complexity from clinical samples. <i>Journal of Virological Methods</i> , 2022, 302, 114493.	1.0	3
61	Liver Disease Due to Alpha-1 Antitrypsin Deficiency: Are We Surprised That It Is More Complex Than We Thought?. <i>Hepatology</i> , 2019, 70, 5-7.	3.6	2
62	Genome-wide capture sequencing to detect hepatitis C virus at the end of antiviral therapy. <i>BMC Infectious Diseases</i> , 2020, 20, 632.	1.3	2
63	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. <i>GastroHep</i> , 2021, 3, 196-208.	0.3	1
64	The AASLD and public policy: Coming in out of the cold. <i>Hepatology</i> , 2007, 45, 1335-1336.	3.6	0
65	Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS-CO13 HEPACOH)" <i>Journal of Hepatology</i> , 2020, 72, 592-593.	1.8	0
66	A novel target enrichment strategy in next-generation sequencing through 7-deaza-dGTP-resistant enzymatic digestion. <i>BMC Research Notes</i> , 2020, 13, 445.	0.6	0
67	Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites. <i>Cureus</i> , 2021, 13, e15403.	0.2	0
68	Meet Your President: Michael W. Fried, M.D., F.A.A.S.L.D.. <i>Hepatology</i> , 2019, 69, 1369-1371.	3.6	0
69	Michael Charles Kew - Frontrunner in Hepatology. <i>Journal of Hepatology</i> , 2022, 76, 754.	1.8	0